Caron Jacobson is an Assistant Professor of Medicine at Harvard Medical School, and a member of the lymphoma group and Medical Director of the Immune Effector Cell Therapy program at Dana-Farber Cancer Institute. Her research focuses on the use of cellular therapies, including CAR T-cell therapies, and other immunotherapies for the treatment of lymphoma.
Caron got her BS in Biology from Brown University and her MD from Columbia College of Physicians and Surgeons. She did her residency in Internal Medicine at Columbia University Medical Center, where she also served as a chief resident. She moved to Boston for her fellowship in hematology/oncology in the joint DFCI/MGH fellowship program, where she completed research projects in transplant immunology under the mentorship of Dr. Jerome Ritz. She transitioned from the Ritz lab into the clinical lymphoma division and received training in the clinical and translational investigation through the Clinical Investigator Training Program at Harvard Medical School, which led to a Masters in Medical Science. She now runs both industry-sponsored and investigator-initiated studies of immunotherapy and cellular therapies for the treatment of B cell lymphomas.
As the Medical Director of the Immune Effector Cell Therapy program at DFCI, Caron oversees both the commercial and research cell therapy programs, which are heavily focused on hematologic malignancies but which is expanding into solid tumours. Her group offers access to three FDA approved CAR T-cell products in lymphoma and leukemia and currently runs over 30 studies across 8 different disease centers.
